Skip to main content

Table 2 Secondary efficacy endpoints

From: A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

 

LY2603618/gemcitabine

Gemcitabine

(n = 65)

(n = 34)

Progression-free survival, mos.

  

 Median (range)

3.5 (0–15.9)

5.6 (0–17.4)

Duration of response, mos.

  

Median (range)

3.5 (1.5–14.1)

6.0 (3.7–6.8)

Best Overall Response, n (%; 95% CI)

 CR

0

0

 PR

14 (21.5%; 12.3–33.5)

3 (8.8%; 1.9–23.7)

 SD

22 (33.8%; 22.6–46.6)

19 (55.9%; 37.9–72.8)

Clinical Benefit Rate, n (%; 95% CI)

36 (55.4%; 42.5–67.7)

22 (64.7%; 46.5–80.3)

  1. CI confidence interval; CR complete response; LY2603618/gemcitabine LY2603618 (230 mg flat dose) combined with gemcitabine 1000 mg/m2; mos months; n number of patients; PR partial response; SD stable disease